Organon & Co. (NYSE:OGN) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Organon & Co. (NYSE:OGN) from a hold rating to a buy rating in a report released on Saturday.

A number of other brokerages have also recently issued reports on OGN. Piper Sandler cut shares of Organon & Co. from an “overweight” rating to an “underweight” rating and set a $5.00 target price for the company. in a report on Monday, October 27th. Barclays initiated coverage on Organon & Co. in a report on Tuesday, December 9th. They issued an “underweight” rating and a $7.50 price target on the stock. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Organon & Co. in a research note on Wednesday, October 8th. JPMorgan Chase & Co. reduced their price objective on Organon & Co. from $14.00 to $12.00 and set an “underweight” rating for the company in a report on Tuesday, November 11th. Finally, Morgan Stanley lowered their target price on Organon & Co. from $10.00 to $9.00 and set an “equal weight” rating on the stock in a report on Tuesday, November 11th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Hold rating and four have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Reduce” and an average target price of $8.38.

Organon & Co. Price Performance

Shares of NYSE OGN opened at $7.42 on Friday. The firm has a market capitalization of $1.93 billion, a P/E ratio of 3.87, a PEG ratio of 1.50 and a beta of 0.58. Organon & Co. has a one year low of $6.18 and a one year high of $17.23. The company’s fifty day moving average is $7.17 and its two-hundred day moving average is $8.87. The company has a debt-to-equity ratio of 9.69, a quick ratio of 1.20 and a current ratio of 1.75.

Organon & Co. (NYSE:OGN) last announced its quarterly earnings results on Monday, November 10th. The company reported $1.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.93 by $0.08. Organon & Co. had a net margin of 7.95% and a return on equity of 143.47%. The business had revenue of $1.60 billion during the quarter, compared to the consensus estimate of $1.57 billion. During the same quarter last year, the firm posted $1.38 EPS. Analysts forecast that Organon & Co. will post 3.68 EPS for the current fiscal year.

Organon & Co. Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, December 11th. Investors of record on Thursday, November 20th were given a dividend of $0.02 per share. This represents a $0.08 annualized dividend and a dividend yield of 1.1%. The ex-dividend date was Thursday, November 20th. Organon & Co.’s payout ratio is currently 4.17%.

Hedge Funds Weigh In On Organon & Co.

Hedge funds have recently bought and sold shares of the stock. State of New Jersey Common Pension Fund D lifted its holdings in Organon & Co. by 69.0% in the 2nd quarter. State of New Jersey Common Pension Fund D now owns 216,737 shares of the company’s stock valued at $2,098,000 after purchasing an additional 88,454 shares in the last quarter. Bryce Point Capital LLC purchased a new position in shares of Organon & Co. during the second quarter valued at approximately $465,000. Douglas Lane & Associates LLC boosted its position in Organon & Co. by 19.0% during the second quarter. Douglas Lane & Associates LLC now owns 315,952 shares of the company’s stock worth $3,058,000 after acquiring an additional 50,393 shares during the last quarter. Triumph Capital Management boosted its position in Organon & Co. by 109.1% during the second quarter. Triumph Capital Management now owns 90,342 shares of the company’s stock worth $875,000 after acquiring an additional 47,127 shares during the last quarter. Finally, WBI Investments LLC purchased a new stake in Organon & Co. in the 1st quarter worth approximately $946,000. Hedge funds and other institutional investors own 77.43% of the company’s stock.

About Organon & Co.

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.